Atom Bioscience’s ABP-745 cleared to enter clinic in US for acute gout
Jan. 2, 2024
Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd. has received FDA clearance of its IND application for a phase I trial in the U.S. of ABP-745, an anti-inflammatory oral small-molecule drug, for the treatment of acute gout.